Top entities: AviadoBio, Lisa Deschamps, Sebastien Ourselin.

What category does this event fall under?

Business — classified as license expansion.

What is the sentiment of coverage?

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business license expansion

AviadoBio expands vMiX license with King's College London

Q: When did this event occur?

First reported Jun 16, 2026; last updated Jun 17, 2026.

Q: What is the market impact?

General. The expanded license agreement between AviadoBio and King s College London is expected to positively impact the biotechnology and pharmaceutical markets by enabling broader application of the vMiX RNAi gene silencing platform.

Analysis based on 6 articles · First reported Jun 16, 2026 · Last updated Jun 17, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The expanded license agreement between AviadoBio and King s College London is expected to positively impact the biotechnology and pharmaceutical markets by enabling broader application of the vMiX RNAi gene silencing platform. This could lead to the development of new therapies across various disease areas, potentially increasing investment and innovation in gene therapy.

Biotechnology Pharmaceuticals

Event Summary

AviadoBio and King s College London announced an expanded license agreement, granting AviadoBio exclusive rights to apply the vMiX RNAi gene silencing platform across all human therapeutic areas. This builds on their 2020 agreement, which focused on neurological diseases, and now includes potential applications in cardiovascular disease, nephrology, oncology, and other indications. The vMiX platform uses AAV for targeted, durable gene silencing, with the potential to silence up to three genes simultaneously. This expansion follows positive preclinical data for AVB-406, AviadoBio's lead vMiX-enabled program in Alzheimer's disease, presented at the American Society of Gene and Cell Therapy 2026 Annual Meeting. The agreement aims to maximize the value of vMiX as a platform technology and facilitate strategic collaborations.

Entities Involved

priv

AviadoBio

AviadoBio expanded its exclusive license agreement with King s College London for the vMiX RNAi gene silencing platform, allowing it to apply the technology across all human therapeutic areas. This positions AviadoBio to maximize the value of vMiX and pursue strategic partnerships beyond its core neuroscience pipeline.

Importance 100.0 Sentiment 75.0

per

Lisa Deschamps

As CEO of AviadoBio, Lisa Deschamps commented on the strategic importance of expanding the vMiX license to maximize its value and explore partnerships.

Importance 30.0 Sentiment 50.0

per

Sebastien Ourselin

As Assistant Principal (Innovation) at King s College London, Professor Sebastien Ourselin highlighted the depth of translational research and the strength of the partnership with AviadoBio.

Importance 20.0 Sentiment 50.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard